温胃舒颗粒联合铝碳酸镁治疗慢性浅表性胃炎的临床研究
|
摘要
目的研究温胃舒颗粒联合铝碳酸镁治疗慢性浅表性胃炎的临床疗效。方法选取2018年1月—2019年1月来中国人民解放军联勤保障部队第九0一医院就诊的慢性浅表性胃炎患者101例,根据入院先后分成对照组(50例)和治疗组(51例)。对照组口服铝碳酸镁片,2片/次,3次/d。治疗组患者在对照组治疗基础上口服温胃舒颗粒,1袋/次,2次/d。两组患者均连续治疗4周。观察两组的临床疗效,比较两组治疗前后证候积分、胃黏膜炎性病变评分、日常生活能力评分、血清列腺素E_2(PGE_2)和超氧化物歧化酶(SOD)的变化情况。结果治疗后,对照组和治疗组的总有效率分别是82.00%、96.08%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者证候积分、胃黏膜炎性病变评分均较治疗前显著降低,而日常生活能力评分明显升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组证候积分、胃黏膜炎性病变评分低于对照组,而日常生活能力评分高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清PGE_2、SOD水平均明显升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组PGE_2、SOD水平显著高于对照组,两组比较差异具有统计学意义(P<0.05)。结论温胃舒颗粒联合铝碳酸镁治疗慢性浅表性胃炎疗效显著,能明显改善患者的临床症状,修复损伤胃黏膜,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Wenweishu Granules combined with hydrotalcite in treatment of chronic superficial gastritis. Methods Patients(101 cases) with chronic superficial gastritis in 901 th Hospital of PLA Joint Logistics Support Force from January 2018 to January 2019 were divided into control(50 cases) and treatment(51 cases) groups based on admission orders. Patients in the control group were po administered with Hydrotalcite Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Wenweishu Granules on the basis of the control group, 1 bag/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of syndrome score, gastric mucosa inflammatory lesion score, daily living ability score, PGE_2 and SOD in two groups before and after treatment were compared. Results After treatment, the angina pectoris efficacy in the control and treatment groups were 82.00% and 96.08%, respectively, and there were differences between two groups(P < 0.05). After treatment, syndrome score, gastric mucosa inflammatory lesion score in two groups were significantly decreased, but daily living ability score in two groups were significantly increased, and there were differences in the same group(P < 0.05). After treatment, syndrome score and gastric mucosa inflammatory lesion score in the treatment group were significantly lower than those in the control group, but daily living ability score was higher than that in the control group, and and there were differences between two groups(P < 0.05). After treatment, PGE_2 and SOD in two groups were significantly increased, and there were differences in the same group(P < 0.05). After treatment, PGE_2 and SOD in the treatment group were significantly higher than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Wenweishu Granules combined with hydrotalcite has significant effect in treatment of chronic superficial gastritis, and can significantly improve the clinical symptoms, and also can repair damaged gastric mucosa, which has a certain clinical application value.
Objective To investigate the clinical efficacy of Wenweishu Granules combined with hydrotalcite in treatment of chronic superficial gastritis. Methods Patients(101 cases) with chronic superficial gastritis in 901 th Hospital of PLA Joint Logistics Support Force from January 2018 to January 2019 were divided into control(50 cases) and treatment(51 cases) groups based on admission orders. Patients in the control group were po administered with Hydrotalcite Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Wenweishu Granules on the basis of the control group, 1 bag/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of syndrome score, gastric mucosa inflammatory lesion score, daily living ability score, PGE_2 and SOD in two groups before and after treatment were compared. Results After treatment, the angina pectoris efficacy in the control and treatment groups were 82.00% and 96.08%, respectively, and there were differences between two groups(P < 0.05). After treatment, syndrome score, gastric mucosa inflammatory lesion score in two groups were significantly decreased, but daily living ability score in two groups were significantly increased, and there were differences in the same group(P < 0.05). After treatment, syndrome score and gastric mucosa inflammatory lesion score in the treatment group were significantly lower than those in the control group, but daily living ability score was higher than that in the control group, and and there were differences between two groups(P < 0.05). After treatment, PGE_2 and SOD in two groups were significantly increased, and there were differences in the same group(P < 0.05). After treatment, PGE_2 and SOD in the treatment group were significantly higher than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Wenweishu Granules combined with hydrotalcite has significant effect in treatment of chronic superficial gastritis, and can significantly improve the clinical symptoms, and also can repair damaged gastric mucosa, which has a certain clinical application value.
引文
[1]赵银彪,陈平.慢性胃炎诊治现状及新认识[J].疾病监测与控制, 2012, 6(9):544-545.
[2]周晓平,钟柏松,仇炎炎.铝碳酸镁药理研究进展及临床应用[J].西北药学杂志, 2001, 16(4):183-184.
[3]张海燕.温胃舒胶囊的药理作用研究[J].科学与财富,2015(2):179.
[4]葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社, 2013:364-367.
[5]孙传兴.临床疾病诊断依据治愈好转标准[M].北京:人民军医出版社, 2002:72.
[6]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社, 2002:124-128.
[7]中华医学会病理分会消化病理学组筹备组.慢性胃炎及上皮性肿瘤胃黏膜活检病理诊断共识[J].中华病理学杂志, 2017, 46(5):289-293.
[8]李奎,窦祖林,万桂芳.日常生活活动分析评估表[J].现代康复, 2001, 5(1):129.
[9]赵雪梅.浅谈慢性浅表性胃炎的临床特点和病因[J].医药前沿, 2011, 1(23):243-244.
[10]中华中医药学会.慢性胃炎诊疗指南[J].中国中医药现代远程教育, 2011, 9(10):123-125.
[11]张玉.新一代抗胃酸新药─铝碳酸镁[J].中国药理学通报, 1995, 11(2):176.
[12]王薇,马明,刘祖雄,等.温胃舒颗粒剂的制备与临床应用[J].中国药师, 2005, 8(1):32-34.
[13]李铁,张席锦.前列腺素E2和生长抑素的胃粘膜保护作用与巯基的关系[J].北京大学学报:医学版,1989, 21(6):476-478.
[14]刘卫红,李萍,张蕾,等.慢性浅表性胃炎中医证型与胃黏膜保护因子的相关性分析[J].北京中医药,2007, 26(1):21-23.
[2]周晓平,钟柏松,仇炎炎.铝碳酸镁药理研究进展及临床应用[J].西北药学杂志, 2001, 16(4):183-184.
[3]张海燕.温胃舒胶囊的药理作用研究[J].科学与财富,2015(2):179.
[4]葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社, 2013:364-367.
[5]孙传兴.临床疾病诊断依据治愈好转标准[M].北京:人民军医出版社, 2002:72.
[6]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社, 2002:124-128.
[7]中华医学会病理分会消化病理学组筹备组.慢性胃炎及上皮性肿瘤胃黏膜活检病理诊断共识[J].中华病理学杂志, 2017, 46(5):289-293.
[8]李奎,窦祖林,万桂芳.日常生活活动分析评估表[J].现代康复, 2001, 5(1):129.
[9]赵雪梅.浅谈慢性浅表性胃炎的临床特点和病因[J].医药前沿, 2011, 1(23):243-244.
[10]中华中医药学会.慢性胃炎诊疗指南[J].中国中医药现代远程教育, 2011, 9(10):123-125.
[11]张玉.新一代抗胃酸新药─铝碳酸镁[J].中国药理学通报, 1995, 11(2):176.
[12]王薇,马明,刘祖雄,等.温胃舒颗粒剂的制备与临床应用[J].中国药师, 2005, 8(1):32-34.
[13]李铁,张席锦.前列腺素E2和生长抑素的胃粘膜保护作用与巯基的关系[J].北京大学学报:医学版,1989, 21(6):476-478.
[14]刘卫红,李萍,张蕾,等.慢性浅表性胃炎中医证型与胃黏膜保护因子的相关性分析[J].北京中医药,2007, 26(1):21-23.